Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan

By: via Benzinga
Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.